Abstract The European LeukemiaNet recently revised both the clinical (2022) and
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …

Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …

To characterize the genomic landscape and leukemogenic pathways of older, newly
diagnosed, non-intensively treated patients with AML and to study the clinical implications …

Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …

Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now
considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) …

Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to
frank relapse if untreated. Recently published small case series show that venetoclax …

Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid
neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined …

In recent years, the therapeutic landscape of myeloid malignancies has been completely
revolutionized by the introduction of several new drugs, targeting molecular alterations or …

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …